Evidence map›Paper›PMID 41245249›Full record

ArticleFrontiers in cellular and infection microbiology2025

Reality check: testing the

Taylor Otwell, Brittany Knight, Michael Coryell, Jennifer Stone, Phillip Davis, Bryan Necciai, Paul Carlson, Shanmuga Sozhamannan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Taylor OtwellIntegrated Health Surveillance and Diagnostics, MRIGlobal, Kansas City, MO, United States.
Brittany KnightIntegrated Health Surveillance and Diagnostics, MRIGlobal, Kansas City, MO, United States.
Michael CoryellLaboratory of Mucosal Pathogens & Cellular Immunology, Division of Bacterial, Parasitic and Allergenic Products, Office of Vaccines Research and Review, Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Jennifer StoneIntegrated Health Surveillance and Diagnostics, MRIGlobal, Kansas City, MO, United States.
Phillip DavisIntegrated Health Surveillance and Diagnostics, MRIGlobal, Kansas City, MO, United States.
Bryan NecciaiDefense Biological Product Assurance Office (DBPAO), Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Enabling Biotechnologies, Frederick, MD, United States.
Paul CarlsonLaboratory of Mucosal Pathogens & Cellular Immunology, Division of Bacterial, Parasitic and Allergenic Products, Office of Vaccines Research and Review, Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Shanmuga SozhamannanDefense Biological Product Assurance Office (DBPAO), Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Enabling Biotechnologies, Frederick, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular diagnostic assays are critical tools to test, diagnose and treat infectious and other diseases. For example, PCR test results have been extremely valuable during the COVID-19 pandemic, not only to provide appropriate health care for infected and symptomatic individuals as needed, but also for implementing public health measures such as test, trace and isolate infected and asymptomatic individuals to prevent further transmission of the virus. Sustained transmission and unhindered proliferation of the pathogen across the population during a continuous, ongoing pandemic such as COVID-19, resulted in many variants with mutations. These mutations may lead to signature erosion, a phenomenon wherein diagnostic tests developed using the genomic sequence of an earlier version of the pathogen, may fail and cause a false negative (FN) result in a sample containing a new variant. We and others have developed applications such as PSET (PCR Signature Erosion Tool) to monitor the performance of diagnostic tests

Indexed as

COVID-19COVID-19 Nucleic Acid TestingMutationPolymerase Chain ReactionSARS-CoV-2Computer SimulationFalse Negative ReactionsGenome, ViralHumansfalse negative (FN)in silico predictionPCR efficiencyqPCRreal time PCRSARS-CoV-2signature erosionwet lab testing

Identifiers

PMID41245249
PMCPMC12615454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.